Nutritional status and nutritional risk in patients with neuroendocrine tumors

Abstract

Background: Malnutrition is frequent among patients with malignancies and associated with impaired function, reduced quality of life and increased mortality. Few data are available in patients with neuroendocrine tumors (NET) on nutritional status, nutritional risk, and nutrition impact symptoms (NIS). We aimed to assess nutritional status (NS) and risk, level of function and associations with NIS in NET patients.

Methods: In a cross-sectional study of NET patients, we measured body mass index (BMI) and handgrip strength (HGS) as markers of NS and muscle function assessed by HGS. The nutritional risk score (NRS) was determined by NRS-2002. NIS was assessed by the eating symptoms questionnaire (ESQ), and disease-related appetite questionnaire (DRAQ).

Results: We included 186 patients (51% women), median age 66 years. We observed low BMI (<20.5 kg/m²) in 12%, low HGS in 25%, and impaired level of function in 43% of the patients. About 38% were at nutritional risk, more frequent in patients with residual disease (45% versus 29%, p < .05). Both low HGS, impaired level of function and being at nutritional risk were associated with the NIS: Nausea, vomiting, stomach ache and dry mouth (p < .05) whereas poor appetite and early satiety were only associated with being at nutritional risk and having impaired level of function (p < .05, all).

Conclusions: Almost 40% of NET patients were at nutritional risk; and 25% had impaired HGS associated with specific NIS that preclude food intake. We recommend that NET outpatients are screened with NRS-2002 and that HGS and NIS are determined if NET patients need nutritional therapy.

Keywords:

• Neuroendocrine tumor
• cancer
• nutritional risk score
• nutrition impact symptoms
• eating symptoms questionnaire
• hand grip strength

Disclosure statement

Authors declare no conflict of interest.

Additional information

Funding

Henning Gr⊘nbaek is on advisory board at Novartis and Ipsen and has received research grants from the NOVO Nordisk Foundation, Intercept and Abbvie.